Immuneering Corporation (IMRX)
Oxford Ledge is still expanding full research coverage of IMRX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical oncology company developing Deep Cyclic Inhibitors, novel anti-cancer medicines targeting MAPK and other signaling pathways.
SEC filings
- 8-K Departure/election of directors or officers 2026-06-15
- 8-K Shareholder vote results 2026-06-11
- 8-K Other material event 2026-06-01
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for IMRX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open IMRX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.